Literature DB >> 30534252

Two-week administration of rivaroxaban resolved left atrial thrombus.

Toru Kato1,2, Masahiro Yasaka3, Taku Yabuki4, Taichi Adachi5, Shigeru Toyoda2, Teruo Inoue2.   

Abstract

An 89-year-old man visited our hospital complaining of palpitation. Electrocardiography showed atrial fibrillation, and transthoracic echocardiography demonstrated a mobile thrombus of 28.6 mm × 20.8 mm in the left atrium. Administration of a direct factor Xa inhibitor rivaroxaban (10 mg/day) was started. The thrombus reduced its size and disappeared completely 2 weeks after the commencement of rivaroxaban treatment. To our knowledge, this is the first case report that rivaroxaban successfully dissolved left atrial thrombus during a short period. Rivaroxaban might have a potential, not only to prevent de novo thrombus formation, but also to dissolve established thrombi by direct inhibition of free and thrombus-associated factor Xa. <Learning objective: The incidence of nonvalvular atrial fibrillation is increasing, and left atrial thrombus is the major cause of cardiogenic thrombo-embolism that we need to prevent. Recently, novel oral anticoagulants have been developed. The effects of these agents on intracardiac thrombus resolution have not been fully elucidated. Data from a large cohort study would be required to assess efficacy of novel oral anticoagulants for thrombus resolution.>.

Entities:  

Keywords:  Anticoagulation; Atrial fibrillation; Intracardiac thrombus; Nonvalvular atrial fibrillation; Rivaroxaban

Year:  2014        PMID: 30534252      PMCID: PMC6279631          DOI: 10.1016/j.jccase.2014.08.006

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  7 in total

1.  Regression of intracardiac thrombus after embolic stroke.

Authors:  M Yasaka; T Yamaguchi; T Miyashita; T Tsuchiya
Journal:  Stroke       Date:  1990-11       Impact factor: 7.914

Review 2.  Frontiers of anticoagulation therapy for atrial fibrillation.

Authors:  Takeshi Yamashita
Journal:  J Cardiol       Date:  2011-04-22       Impact factor: 3.159

Review 3.  Dabigatran and left atrial appendage thrombus.

Authors:  Alejandro Vidal; Gabriel Vanerio
Journal:  J Thromb Thrombolysis       Date:  2012-11       Impact factor: 2.300

4.  Left atrial thrombus and prognosis after anticoagulation therapy in patients with atrial fibrillation.

Authors:  Shota Fukuda; Hiroyuki Watanabe; Kenei Shimada; Masaru Aikawa; Yasushi Kono; Satoshi Jissho; Haruyuki Taguchi; Jun Umemura; Minoru Yoshiyama; Takahiro Shiota; Tetsuya Sumiyoshi; Junichi Yoshikawa
Journal:  J Cardiol       Date:  2011-08-06       Impact factor: 3.159

5.  Tissue factor-mediated activation of the prothrombin complex concentrate (PCC) is differently inhibited by dabigatran, rivaroxaban, and apixaban: potential clinical implication.

Authors:  Nasiredin Sadeghi; Daniel Kahn; Walter Jeske; Debra Hoppensteadt; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2013-03-04       Impact factor: 2.389

6.  Increase in the Size of an Intracardiac Thrombus during Dabigatran Therapy (110 mg b.i.d.) in an Acute Cardioembolic Stroke Patient.

Authors:  Emi Tabata; Masahiro Yasaka; Yoshiyuki Wakugawa; Motohiro Komori; Kohta Mori; Yuichiro Tsurusaki; Kazuhito Kokuba; Yoshiki Sambongi; Koichiro Maeda; Yasushi Okada
Journal:  Cerebrovasc Dis Extra       Date:  2013-05-03

7.  Dabigatran for left atrial thrombus.

Authors:  Sae Morita; Yoichi Ajiro; Yoshie Uchida; Kazunori Iwade
Journal:  Eur Heart J       Date:  2013-05-22       Impact factor: 29.983

  7 in total
  2 in total

1.  Resolution of Internal Carotid Arterial Thrombus by the Thrombolytic Action of Dabigatran: A first case report.

Authors:  Hisanao Akiyama; Masashi Hoshino; Takahiro Shimizu; Yasuhiro Hasegawa
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

2.  The resolution of carotid arterial thrombus by oral anticoagulation after IV thrombolysis for chemotherapy-induced stroke: A case report.

Authors:  Bo-Chang Wu; Ming-Hung Hu; Vinchi Wang
Journal:  Medicine (Baltimore)       Date:  2020-08-28       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.